stockrow
Saturday 7 November 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.
- Revenue
- +40.4%
- EPS
- +36.5%
- Free cash flow
- +27.7%
- Total debt
- −2.96%
Quarter to September 2026, against a year earlier
21.62
0.61
+2.90%
Follow QURE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 4 | 5 |
+8 more TTM periods Free account |
| (88.99%) | (157.61%) | (228.24%) | (207.10%) | ||
| (25.47%) | (32.13%) | (30.18%) | (28.81%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.26%) | (33.09%) | (36.74%) | (32.79%) | |
Average Days of Receivables |
86.95 | 112.95 | 71.86 | 132.94 | |
Free Cash Flow per Share |
(2.76) | (2.44) | (2.75) | (3.10) | |
Free Cash Flow |
(192.96) | (161.45) | (172.56) | (178.40) | |
Capital Expenditures |
(0.74) | (0.66) | (0.45) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(19.04%) | (13.63%) | (21.96%) | (20.48%) | |
Accounts Receivable Turnover |
4.64 | 3.28 | 5.95 | 2.74 | |
Accounts Payable Turnover |
0.20 | 0.27 | 0.35 | 0.27 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
1,817.05 | 1,296.24 | 940.07 | 1,119.25 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.03 | 0.03 | 0.03 | |
Research and Development Expense of Revenue |
661.68% | 708.49% | 739.01% | 873.85% | |
Selling, General and Administrative Expense of Revenue |
411.38% | 420.32% | 412.40% | 406.61% | |
Share Based Compensation of Revenue |
100.24% | 97.96% | 101.47% | 109.82% | |
Interest Coverage |
(3.51) | (3.35) | (3.15) | (2.99) | |
Operating CF/Net income |
0.83 | 0.64 | 0.82 | 0.89 | |
Depreciation/Fixed assets |
1.64 | 1.27 | 1.10 | 1.07 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.03) | (0.03) | |
Revenue per Share |
0.29 | 0.28 | 0.29 | 0.28 | |
Operating CF per Share |
(2.75) | (2.43) | (2.74) | (3.09) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026